VUMERITY caps 231 mg bte 360 pce

7680680660027 CH-68066 L04AX09 01.99.0.
VUMERITY caps 231 mg bte 360 pce
VUMERITY caps 231 mg bte 360 pce
VUMERITY caps 231 mg bte 360 pce
1 / 3
google

Details

Product number
6806601
CPT
-
Packaging group
360
Unit
Kapsel(n)
Composition
diroximeli fumaras 231 mg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, crospovidonum, cellulosum microcristallinum, silica colloidalis anhydrica, triethylis citras, talcum, magnesii stearas, Kapselhülle: hypromellosum, E 171, kalii chloridum, carrageenanum, aqua, Drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, E 172 (nigrum), kalii hydroxidum pro capsula.

Articles (1)

Vumerity 231 mg, Magensaftresistente Hartkapseln
Magensaftresistente Hartkapseln
360
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
30/07/2024
Patient information leaflet
Français
30/07/2024
Patient information leaflet
Italien
30/07/2024
Professional SmPC
Allemand
29/07/2024
Professional SmPC
Français
29/07/2024
Professional SmPC
Italien
29/07/2024

Detailed composition

Substance Quantity Type Category
(N/A)
231.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 3584.85
Specialties list
Yes
Generic
No
SL addition date: 01/11/2021

Authorization holder

Biogen Switzerland AG

6340 Baar

Authorization information

Swissmedic authorization number
68066
Drug name
Vumerity, Magensaftresistente Hartkapseln
Galenic form
KAHAM
ATC Code
L04AX09
Authorization status
Z
Dispensation category
B
First authorization
20/09/2021
Authorization expiration date
19/09/2026
IT number
01.99.0.
Domain
Human medicine
Field of application
Vumerity ist für die Behandlung von Patienten mit schubförmig remittierend verlaufender Multipler Sklerose (MS) zur Reduzierung der Schubhäufigkeit indiziert.

Packaging details

Description (FR)
VUMERITY caps 231 mg bte 360 pce
Description (DE)
VUMERITY Kaps 231 mg Ds 360 Stk
Market launch
20/09/2021
Narcotic (BTM)
No

Other packaging sizes

VUMERITY caps 231 mg bte 120 pce
120 KAP
GTIN: 7680680660010
View